---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012101"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2025-08-15T23:59:59+00:00"
generated_at: "2026-05-17T12:27:40.076923+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Intelligent Bio Solutions Q4 revenue up 16% YoY to $844K; progress on FDA 510(k) for U.S. market

## Summary
- Q4 FY2025 revenue $843,884 (+16% YoY); cartridge sales up 24% YoY.
- Added 115 new accounts in FY2025; active base >450 across 24 countries with 18 distributors.
- FDA 510(k) submission in progress for opiate test system; seeking U.S. clearance beyond Forensic Use Only.
- Operational improvements: multilingual system, HubSpot CRM, new U.S. patent; accounting system upgrade underway.
- Net loss or EPS not disclosed; company reports 'reduced net loss' but no specific figures.

## SEC filing metadata
- accession: 0001493152-25-012101
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2025-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315225012101/0001493152-25-012101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315225012101/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012101
- JSON: https://secwatch.observer/filing/0001493152-25-012101.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.